Next Article in Journal
Technical Developments and Clinical Use of Telemedicine in Sleep Medicine
Next Article in Special Issue
A Systematic Review of the Role of Dysfunctional Wound Healing in the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis
Previous Article in Journal
A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy
Previous Article in Special Issue
Diaphragm Dysfunction: Diagnostic Approaches and Management Strategies
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2016, 5(12), 115; doi:10.3390/jcm5120115

Bronchiectasis in the Last Five Years: New Developments

1
Department of Respiratory Medicine, Western Health, Melbourne 3011, VIC, Australia
2
Department of Respiratory Medicine, Prince of Wales, Sydney 2031, NSW, Australia
3
Department of Respiratory Medicine, Middlemore Hospital, Auckland 2025, New Zealand
4
Melbourne Medical School Western Precinct, The University of Melbourne, Melbourne 3021, VIC, Australia
*
Author to whom correspondence should be addressed.
Academic Editor: David Barnes
Received: 28 September 2016 / Revised: 24 November 2016 / Accepted: 25 November 2016 / Published: 8 December 2016
(This article belongs to the Special Issue Chronic Respiratory Diseases)
View Full-Text   |   Download PDF [246 KB, uploaded 8 December 2016]

Abstract

Bronchiectasis, a chronic lung disease characterised by cough and purulent sputum, recurrent infections, and airway damage, is associated with considerable morbidity and mortality. To date, treatment options have been limited to physiotherapy to clear sputum and antibiotics to treat acute infections. Over the last decade, there has been significant progress in understanding the epidemiology, pathophysiology, and microbiology of this disorder. Over the last five years, methods of assessing severity have been developed, the role of macrolide antibiotic therapy in reducing exacerbations cemented, and inhaled antibiotic therapies show promise in the treatment of chronic Pseudomonas aeruginosa infection. Novel therapies are currently undergoing Phase 1 and 2 trials. This review aims to address the major developments within the field of bronchiectasis over this time. View Full-Text
Keywords: bronchiectasis; severity scores; microbiome; comorbidities; treatment bronchiectasis; severity scores; microbiome; comorbidities; treatment
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Khoo, J.K.; Venning, V.; Wong, C.; Jayaram, L. Bronchiectasis in the Last Five Years: New Developments. J. Clin. Med. 2016, 5, 115.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top